It is hard to get excited after looking at Guangzhou Kingmed Diagnostics Group’s (SHSE:603882) recent performance, when its stock has declined 6.4% over the past month. However, a closer look at its sound financials might cause you to think again. Given that fundamentals usually drive long-term market outcomes, the company is worth looking at. Particularly, we will be paying attention to Guangzhou Kingmed Diagnostics Group’s ROE today.
Return on equity or ROE is a key measure used to assess how efficiently a company’s management is utilizing the company’s capital. In short, ROE shows the profit each dollar generates with respect to its shareholder investments.
View our latest analysis for Guangzhou Kingmed Diagnostics Group
How Is ROE Calculated?
The formula for return on equity is:
Return on Equity = Net Profit (from continuing operations) ÷ Shareholders’ Equity
So, based on the above formula, the ROE for Guangzhou Kingmed Diagnostics Group is:
10% = CN¥874m ÷ CN¥8.7b (Based on the trailing twelve months to September 2023).
The ‘return’ is the income the business earned over the last year. So, this means that for every CN¥1 of its shareholder’s investments, the company generates a profit of CN¥0.10.
What Is The Relationship Between ROE And Earnings Growth?
We have already established that ROE serves as an efficient profit-generating gauge for a company’s future earnings. We now need to evaluate how much profit the company reinvests or “retains” for future growth which then gives us an idea about the growth potential of the company. Generally speaking, other things being equal, firms with a high return on equity and profit retention, have a higher growth rate than firms that don’t share these attributes.
Guangzhou Kingmed Diagnostics Group’s Earnings Growth And 10% ROE
When you first look at it, Guangzhou Kingmed Diagnostics Group’s ROE doesn’t look that attractive. However, the fact that the its ROE is quite higher to the industry average of 7.9% doesn’t go unnoticed by us. Even more so after seeing Guangzhou Kingmed Diagnostics Group’s exceptional 34% net income growth over the past five years. Bear in mind, the company does have a moderately low ROE. It is just that the industry ROE is lower. So, there might well be other reasons for the earnings to grow. For example, it is possible that the broader industry is going through a high growth phase, or that the company has a low payout ratio.
Next, on comparing with the industry net income growth, we found that Guangzhou Kingmed Diagnostics Group’s growth is quite high when compared to the industry average growth of 7.0% in the same period, which is great to see.
Earnings growth is an important metric to consider when valuing a stock. It’s important for an investor to know whether the market has priced in the company’s expected earnings growth (or decline). Doing so will help them establish if the stock’s future looks promising or ominous. Is Guangzhou Kingmed Diagnostics Group fairly valued compared to other companies? These 3 valuation measures might help you decide.
Is Guangzhou Kingmed Diagnostics Group Efficiently Re-investing Its Profits?
Guangzhou Kingmed Diagnostics Group has a really low three-year median payout ratio of 21%, meaning that it has the remaining 79% left over to reinvest into its business. So it seems like the management is reinvesting profits heavily to grow its business and this reflects in its earnings growth number.
Moreover, Guangzhou Kingmed Diagnostics Group is determined to keep sharing its profits with shareholders which we infer from its long history of six years of paying a dividend. Our latest analyst data shows that the future payout ratio of the company over the next three years is expected to be approximately 24%. However, Guangzhou Kingmed Diagnostics Group’s ROE is predicted to rise to 13% despite there being no anticipated change in its payout ratio.
Summary
In total, we are pretty happy with Guangzhou Kingmed Diagnostics Group’s performance. In particular, it’s great to see that the company has seen significant growth in its earnings backed by a respectable ROE and a high reinvestment rate. On studying current analyst estimates, we found that analysts expect the company to continue its recent growth streak. To know more about the company’s future earnings growth forecasts take a look at this free report on analyst forecasts for the company to find out more.
Valuation is complex, but we’re helping make it simple.
Find out whether Guangzhou Kingmed Diagnostics Group is potentially over or undervalued by checking out our comprehensive analysis, which includes fair value estimates, risks and warnings, dividends, insider transactions and financial health.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
